Lineage Cell Therapeutics Q4 Earnings Call Highlights

Key Points

• Lineage reports cash of $55.8 million (plus ~$5.4 million in March warrant proceeds) and expects to fund planned operations into Q2 2028, a runway extended by a $21M ATM, warrant exercises and a $5M Roche/Genentech milestone.
• OpRegen partner activity has accelerated—Roche/Genentech added 10 clinical sites to the GALE Phase 2a study (now 17 sites), the program holds RMAT status, and partners’ analysis suggested a single dose could yield visual improvement for at least three years.
• AlloSCOPE underpins Lineage’s manufacturing strategy: the company has built GMP master/working cell banks and clinical-grade product, met an initial go/no-go on a new islet cell program, and is prioritizing scalable production of undifferentiated cells plus a “5D engineering” approach combining 2D control with 3D efficiency.

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early internal validation work in a newly launched islet cell research initiative. Management also reviewed updates across its three most visible programs—OpRegen in geographic atrophy, OPC1 in spinal cord injury, and Resonance in hearing loss—while outlining how its AlloSCOPE platform underpins a strategy of building additional cell therapy assets and selectively partnering them.

Partner activity around OpRegen and GALE site expansion

Chief Executive Officer Brian Culley said the company continues to view OpRegen—its retinal pigment epithelium (RPE) cell transplant program for dry age-related macular degeneration (AMD) with geographic atrophy (GA)—as the most advanced program and a “critical case study” for its approach to cell transplantation. Culley reiterated previously discussed observations from analyses of Lineage’s Phase 1/2a work, stating Roche and Genentech analysis indicated a single dose of OpRegen could provide visual improvement lasting at least three years when delivered to the target location.

While emphasizing the company has no guidance on timing of additional trials or data disclosures from partners, Culley said Roche and Genentech have “somewhat suddenly” opened 10 new clinical sites in the GALE Phase 2a surgical optimization study over the last nine months, bringing the trial to 17 locations. He described the acceleration in site openings as a favorable sign that could support preparations for later-stage trials.

Culley also pointed to other partner actions as supportive indicators, including Genentech’s acquisition of proprietary surgical delivery devices from a competitor and the program’s RMAT designation. He noted Lineage received its first $5 million development milestone payment in December under the Roche/Genentech collaboration.

Manufacturing focus: AlloSCOPE and “better from the beginning”

Culley spent considerable time on manufacturing, describing AlloSCOPE—an acronym for “allogeneic, scalable, consistent, off-the-shelf, pluripotent cell engineering”—as a core platform designed to address challenges such as donor variability and manufacturing cost seen with autologous approaches. He said Lineage has established a GMP master cell bank and GMP working cell bank and generated clinical-grade product used in an FDA-cleared clinical trial.

Management framed this as evidence that Lineage’s cell banking system could be repeated as needed and scaled to “millions of vials” and “trillions of cells.” Culley argued early investment in scalable, reproducible processes is essential because “the process is the product” in cell therapy and early clinical manufacturing must align with eventual commercial scale.

Islet cell research initiative reaches an initial internal milestone

Lineage also provided its most detailed discussion to date of a new type 1 diabetes islet cell research initiative. Culley said the company met its initial internal go/no-go development milestone, which allowed the effort to proceed to the next phase of internal development.

He framed the primary opportunity as solving the supply and scale issues that limit the feasibility of commercial islet cell transplants. Culley said doses may require up to 1 billion cells per patient and that commercial viability may require “thousands of doses per batch,” which the company estimates could imply at least an 80-liter bioreactor scale. He argued an unresolved bottleneck is generating the billions of undifferentiated pluripotent stem cells needed to feed such a differentiation process, while maintaining pluripotency and genetic stability.

The strategy described on the call included two components:

• Scaling undifferentiated cells first: Culley said Lineage is “inverting the traditional development paradigm” by focusing on scalable production of undifferentiated cells before finalizing immunosuppression strategies or other downstream elements.
• Combining 2D control with 3D efficiency: Using AlloSCOPE, the company aims to merge the control of 2D culture with the volumetric efficiency of 3D systems—an approach Culley referred to as “5D engineering.” He said Lineage has reduced this to practice multiple times at half-liter scale and is now evaluating translation into multi-liter vessels.

In Q&A, Culley said the company cannot predict linearity as it scales from half-liter to multi-liter and ultimately to large bioreactors, but he suggested the step from “0 to a half liter” was a larger achievement than the next incremental scaling steps. He also said the approach is intended to be capital-efficient by putting “the least expensive and most challenging step first.”

Program updates: OPC1, Resonance, and pipeline expansion

For OPC1 in spinal cord injury (SCI), Culley said the company is enrolling the DOSED study, a safety and device performance trial evaluating a proprietary delivery system designed to administer cells without stopping patient ventilation. He noted Lineage treated its “first-ever chronic SCI patient” and said the participant completed a six-month safety follow-up with no significant safety events and that the device performed as planned. The company also opened a second DOSED clinical site at Rancho Research Institute in conjunction with Rancho Los Amigos National Rehab Center.

Culley emphasized DOSED is not designed as an efficacy study, though functional assessments are being collected. He said the trial collects baseline and early functional assessments within the first 90 days, with a focus on one-year functional assessments as potentially more meaningful. He also said the first participant met criteria for ASIA impairment A and that Lineage amended the protocol to broaden enrollment after difficulty finding the originally agreed enrollment “stagger,” adding it had identified another patient who may be treated in the coming weeks.

On Resonance (ANP1), the company’s auditory neuronal cell transplant program for hearing loss, Culley said Lineage achieved its 2025 objective to secure funding partnerships by signing an agreement with William Demant Invest (WDI) expected to fund planned preclinical development through IND stage. He said the work demonstrated Lineage could generate new IP and advance a new AlloSCOPE-derived product candidate into preclinical testing within a year with a modest investment.

Management also discussed business development strategy, with Culley saying the company is mindful of cost of capital and risk and does not have a fixed objective to launch all products internally. He said Lineage seeks to create a “basket of assets” that can be partnered early to offset reliance on traditional capital markets, while retaining meaningful ownership in partnerships. Culley added Lineage expects to disclose “another new cell type” as early as the next three to six weeks, though he did not provide details.

Separately, Culley addressed a question about a hypoimmune iPSC line obtained through a Factor alliance, stating it was designed for an undisclosed neurological indication. He said Lineage is “indifferent” between iPSC and embryonic stem cell sources and follows data and line behavior, adding that Factor’s gene-editing and hypoimmunity expertise was an external capability Lineage chose not to build in-house.

Financial results: revenue lift from collaborations and extended runway

Chief Financial Officer Jill Howe said the company’s full-year net loss increased significantly versus 2024, driven mainly by non-cash charges tied to an increased warrant liability from the share price rise and a non-cash charge related to an asset acquired in 2018 that the company elected to no longer develop. She also said OpRegen costs appeared higher due to accounting treatment tied to downstream obligations after the first Roche/Genentech milestone payment; excluding that treatment, OpRegen development expenses were lower year over year.

Howe reported cash of $55.8 million as of December 31, 2025. Combined with approximately $5.4 million in warrant exercise proceeds received in March, she said Lineage expects to fund planned operations into Q2 2028. She attributed the longer runway versus prior guidance primarily to $21 million in gross proceeds from an ATM block trade in November, the March warrant exercise proceeds, and the $5 million Roche/Genentech milestone payment.

For the fourth quarter, the company reported total revenue of approximately $6.6 million, operating expenses of $13.2 million, and a loss from operations of $6.5 million. Howe said net income attributable to Lineage for the quarter was $0.9 million, or $0.004 per share, compared with a net loss of $3.3 million, or $0.02 per share, in the year-ago period.

For the full year, Howe reported revenue of $14.6 million, operating expenses of $51.2 million, loss from operations of $36.6 million, and net loss attributable to Lineage of $63.5 million, or $0.28 per share, compared with a net loss of $18.6 million, or $0.09 per share, for 2024. She said the year-over-year change reflected the non-cash warrant liability remeasurement and an impairment related to a prior acquisition.

Howe noted the runway guidance includes only the $5.4 million of warrants exercised in March and does not include the roughly $32 million of remaining underlying warrants priced at $0.91 per share. She said those warrants could be accelerated if Roche or Genentech publicly discloses intent to advance OpRegen into trials with a comparator arm.

About Lineage Cell Therapeutics NYSEAMERICAN: LCTX

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.